Accordingly, we propose it may be possible to tread the path set for the first DMD exon skipping study reported by Kinali and colleagues56: an intramuscular injection into late-onset Pompe disease patients as a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. This evidence concerns the gene DMD and glycogen storage disease II.